Castle Biosciences Inc Stock News

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek J. Maetzold - Founder, CEO, President & Director Frank Stokes - CFO & Treasurer Conference Call Participants Catherine Walden Ramsey Schulte - Robert W.

Castle (CSTL) Q2 Revenue Tops Estimates

Delivered Q2 2025 revenue of $86 million Q 2 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 33% over Q 2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CST...

Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET

FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated ou...

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in ...

FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss i...